TMK ADS (TMKXY) Financials Nov 14, 2014, 8:10 p.m.
Income
TMK ADS (TMKXY) Financials Nov 14, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for TMK ADS
Fiscal year is January-December. All values RUB millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 109.86B 169.49B 198.56B 207.8B 204.98B
Cost of Goods Sold (COGS) incl. D&A 96.02B 133.07B 156.86B 163.71B 163.62B
COGS excluding D&A 86.08B 123.56B 146.94B 4.94B 153.23B
Depreciation & Amortization Expense 9.94B 9.51B 9.92B 326.06M 10.39B
Depreciation 6.52B - - 266.45M 8.82B
Amortization of Intangibles 3.42B - - 59.61M 1.56B
Gross Income 13.84B 36.42B 41.7B 44.09B 41.36B
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 13.17B 17.16B 18.7B 21.23B 21.09B
Research & Development 307.2M 384.81M 520.02M 15.96M 398.91M
Other SG&A 405.19M 552.26M 618.46M 667.42M 649.23M
Other Operating Expense 730.16M 1.06B 3.2B 1.89B 1.48B
Unusual Expense 1.5B 375.54M (3.32B) 492.24M (97.33M)
EBIT after Unusual Expense (1.5B) (375.54M) 3.32B (492.24M) 97.33M
Non Operating Income/Expense 2.08B 796.9M 1.69B 31.66M (1.03B)
Non-Operating Interest Income 74.53M 91.87M 97.99M 6.72M 133.21M
Equity in Affiliates (Pretax) - 0 - - -
Interest Expense 14.18B 13.08B 8.9B 9.23B 8.04B
Gross Interest Expense 14.18B 13.08B 8.9B 300.37M 8.58B
Interest Capitalized 0 0 0 3.27M 540.88M
Pretax Income (13.59B) 5.63B 16B 12.43B 9.95B
Income Tax (3.27B) 2.47B 4.69B 3.81B 3.12B
Income Tax - Current Domestic (583.26M) 1.51B 2.86B 101.54M 2.56B
Income Tax - Current Foreign - - - - -
Income Tax - Deferred Domestic (2.69B) 951.42M 1.82B 21.09M 557.01M
Income Tax - Deferred Foreign - - - - -
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 44.95M 0 (5.44M) 1.27M 5.61M
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (10.28B) 3.16B 11.31B 8.62B 6.84B
Minority Interest Expense (254.54M) (7.9M) 134.28M 153.25M 19.47M
Net Income (10.02B) 3.17B 11.18B 8.47B 6.82B
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (10.02B) 3.17B 11.18B 8.47B 6.82B
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (10.02B) 3.17B 11.18B 8.47B 6.82B
EPS (Basic) (11.42) 3.65 12.94 9.94 7.97
Basic Shares Outstanding 866.62M 860.48M 864.98M 863.31M 865.03M
EPS (Diluted) (11.42) 3.65 11.76 9.94 7.97
Diluted Shares Outstanding 866.62M 860.48M 936.75M 863.31M 865.03M
EBITDA 9.88B 27.7B 29.72B 31.09B 29.18B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...
Continue Reading
Shenzhen Steps into the Arbitration Spotlight In a move that's bound to tweak some eyebrows in the legal realm, Shenzhen just hosted the 2026 Foreign Direct Investment International Arbitration Moot (FDI Moot) Global Finals. This marks the first time the finals have landed on Chinese soil, and folks, that's a big deal. It’s a hefty nod to China's expanding credibility...
Continue Reading
A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...
Continue Reading
Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...
Continue Reading
Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...
Continue Reading
Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...
Continue Reading
Clarins Takes Austin by Storm Under the vast Austin sky, something remarkable unfolded as Clarins transformed the scene with a flashy rooftop affair that screamed innovation and elegance. They weren’t just showing off fancy bottles of beauty potion; they were stirring the pot, merging science with a splash of high-end glitz. This wasn’t just another product pitch—it...
Continue Reading
Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...
Continue Reading
Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...
Continue Reading
Why a Trade Fair Needs Lion Dances October 2026 marks a time when talking about a trade fair means diving headfirst into a whirlpool of global exchange and cultural tango we don’t often see in the West. Yeah, I'm looking at you, Canton Fair—a long-runner over in China that's managed to haul in the globe to not just showcase wares, but bring people together in a clash...
Continue Reading
Top 5 Most Recently Viewed Articles
Overview of Horizon Resources Inc.'s New Valuation Horizon Petroleum Ltd. (TSXV: HPL) is thrilled to share the latest updates on significant reserve and resource assessments for its operations in Poland. The company has successfully acquired key assets in the Bielsko-Biala concession affecting the Lachowice gas field. Enjoying the benefits of acquisition through its...
Continue Reading
Revolutionizing Women's Lingerie: Thirdlove's New TempSync™ Collection Thirdlove, a pioneering lifestyle brand dedicated to women's comfort and inclusion, has officially unveiled its innovative TempSync collection. This unique line of temperature-regulating lingerie comprises a T-shirt bra, wireless bra, and hipster, all designed to support women during perimenopause...
Continue Reading
Queclink's Innovative WR310 Series: A New Era of Connectivity Queclink, a global leader in IoT solutions, has proudly launched the WR310 Series, an advanced industrial router designed to meet the burgeoning demands of modern industrial networks. Tailored to provide seamless connectivity, the WR310 Series is set to redefine industrial communications while elevating...
Continue Reading
PRA Celebrates New Steps Towards Healthcare Price Transparency Ensuring patients receive accurate pricing information before they receive care has become a crucial conversation in healthcare. The Patient Rights Advocate (PRA) has taken a momentous stance by applauding recent actions that promote transparency within the healthcare sector. PRA's Support for HHS Initiatives...
Continue Reading
Stifel Financial Corp Shows Significant Q3 Growth Stifel Financial Corp (NYSE: SF) has announced remarkable growth in its third-quarter financial performance. With net revenue reaching $1.23 billion, the company marked a significant 17% rise year-over-year. This impressive figure is notable as it stands as the second-highest quarterly revenue in its history. Additionally,...
Continue Reading